Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease.

PMID: 29178139
Journal: GLIA
Year: 2018
Reference: Glia. 2018 Mar;66(3):637-653. doi: 10.1002/glia.23270. Epub 2017 Nov 27.
Impact factor:
Publication type: Paper in international publication
Authors: Comella, Joan X; Davila, Jose C; Fernandez-Valenzuela, Juan Jose; Galea, Elena; Gomez-Arboledas, Angela; Gutierrez, Antonia; Navarro, Victoria; Nunez-Diaz, Cristina; Sanchez-Mejias, Elisabeth; Sanchez-Mico, Maria Virtudes et al.
DOI: 10.1002/glia.23270

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

PMID: 30018749
Journal: Oncotarget
Year: 2018
Reference: Oncotarget. 2018 Jun 26;9(49):29238-29258. doi: 10.18632/oncotarget.25579. eCollection 2018 Jun 26.
Impact factor: 0
Publication type: Review in national publication
Authors: Cullell, Natalia, Carrera, Caty, Muino, Elena, Torres, Nuria, Krupinski, Jerzy, Fernandez-Cadenas, Israel et al.
DOI: 10.18632/oncotarget.25579

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

PMID: 30018749
Journal: Oncotarget
Year: 2018
Reference: Oncotarget. 2018 Jun 26;9(49):29238-29258. doi: 10.18632/oncotarget.25579. eCollection 2018 Jun 26.
Impact factor:
Publication type: Review in national publication
Authors: Carrera, Caty; Cullell, Natalia; Fernandez-Cadenas, Israel; Krupinski, Jerzy; Muino, Elena; Torres, Nuria et al.
DOI: 10.18632/oncotarget.25579

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

PMID: 29965950
Journal: TRANSPLANTATION
Year: 2018
Reference: Transplantation. 2018 Oct;102(10):e439-e446. doi: 10.1097/TP.0000000000002348.
Impact factor: 3.96
Publication type: Paper in international publication
Authors: Roman, Antonio, Vima, Jaume, Sintes, Helena, Saez-Gimenez, Berta, Berastegui, Cristina, Lopez-Meseguer, Manuel, Monforte, Victor, Bravo, Carlos, Gomez-Olles, Susana et al.
DOI: 10.1097/TP.0000000000002348

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

PMID: 29965950
Journal: TRANSPLANTATION
Year: 2018
Reference: Transplantation. 2018 Oct;102(10):e439-e446. doi: 10.1097/TP.0000000000002348.
Impact factor:
Publication type: Paper in international publication
Authors: Berastegui, Cristina; Bravo, Carlos; Gomez-Olles, Susana; Lopez-Meseguer, Manuel; Monforte, Victor; Roman, Antonio; Saez-Gimenez, Berta; Sintes, Helena; Vima, Jaume et al.
DOI: 10.1097/TP.0000000000002348

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

PMID: 29237008
Journal: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Year: 2018
Reference: J Antimicrob Chemother. 2018 Mar 1;73(3):732-737. doi: 10.1093/jac/dkx459.
Impact factor: 5.071
Publication type: Paper in international publication
Authors: Khoo, Saye, Molto, Jose, Curran, Adrian, Miranda, Cristina, Challenger, Elizabeth, Santos, Jose Ramon, Ribera, Esteban, Clotet, Bonaventura, Valle, Marta et al.
DOI: 10.1093/jac/dkx459

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

PMID: 29237008
Journal: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Year: 2018
Reference: J Antimicrob Chemother. 2018 Mar 1;73(3):732-737. doi: 10.1093/jac/dkx459.
Impact factor:
Publication type: Paper in international publication
Authors: Challenger, Elizabeth; Clotet, Bonaventura; Curran, Adrian; Khoo, Saye; Miranda, Cristina; Molto, Jose; Ribera, Esteban; Santos, Jose Ramon; Valle, Marta et al.
DOI: 10.1093/jac/dkx459

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

PMID: 29185897
Journal: SUBSTANCE USE & MISUSE
Year: 2018
Reference: Subst Use Misuse. 2018 Jul 3;53(8):1267-1274. doi: 10.1080/10826084.2017.1402056. Epub 2017 Nov 29.
Impact factor: 1.132
Publication type: Paper in international publication
Authors: Grau-Lopez, L, Grau-Lopez, L, Daigre, C, Palma-Alvarez, R F, Rodriguez-Cintas, L, Ros-Cucurull, E, Roncero, C et al.
DOI: 10.1080/10826084.2017.1402056

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

PMID: 29185897
Journal: SUBSTANCE USE & MISUSE
Year: 2018
Reference: Subst Use Misuse. 2018 Jul 3;53(8):1267-1274. doi: 10.1080/10826084.2017.1402056. Epub 2017 Nov 29.
Impact factor:
Publication type: Paper in international publication
Authors: Daigre, C; Grau-Lopez, L; Grau-Lopez, L; Palma-Alvarez, R F; Palma-Alvarez, R F; Rodriguez-Cintas, L; Roncero, C; Ros-Cucurull, E et al.
DOI: 10.1080/10826084.2017.1402056

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

PMID: 30545466
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2018
Reference: Enferm Infecc Microbiol Clin. 2018 Dec;36 Suppl 2:10-16. doi: 10.1016/S0213-005X(18)30392-6.
Impact factor: 1.707
Publication type: Paper in national publication
Authors: Curran, Adrian, Navarro, Jordi et al.
DOI: 10.1016/S0213-005X(18)30392-6

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

PMID: 30545466
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2018
Reference: Enferm Infecc Microbiol Clin. 2018 Dec;36 Suppl 2:10-16. doi: 10.1016/S0213-005X(18)30392-6.
Impact factor:
Publication type: Paper in national publication
Authors: Curran, Adrian; Navarro, Jordi et al.
DOI: 10.1016/S0213-005X(18)30392-6

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

PMID: 29882016
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2018
Reference: Cancer Chemother Pharmacol. 2018 Aug;82(2):285-298. doi: 10.1007/s00280-018-3610-z. Epub 2018 Jun 7.
Impact factor: 2.808
Publication type: Paper in international publication
Authors: Krop, Ian E, Rodon, Jordi, Perez-Fidalgo, Alejandro, Britten, Carolyn D, Becerra, Carlos, Schellens, Jan, Richards, Donald A, Schuler, Martin, Abu-Khalaf, Maysa, Johnson, Faye M et al.
DOI: 10.1007/s00280-018-3610-z

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

PMID: 29882016
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2018
Reference: Cancer Chemother Pharmacol. 2018 Aug;82(2):285-298. doi: 10.1007/s00280-018-3610-z. Epub 2018 Jun 7.
Impact factor:
Publication type: Paper in international publication
Authors: Abu-Khalaf, Maysa; Baselga, Jose; Becerra, Carlos; Britten, Carolyn D; Burris, Howard; Demanse, David; Duval, Vincent; Edenfield, Jeff; Guerrero-Zotano, Angel; Hackl, Wolfgang et al.
DOI: 10.1007/s00280-018-3610-z

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

PMID: 29247830
Journal: Journal of Thoracic Oncology
Year: 2018
Reference: J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.
Impact factor: 10.336
Publication type: Paper in international publication
Authors: Garon, Edward B, Akimov, Mikhail, Felip, Enriqueta, Barlesi, Fabrice, Besse, Benjamin, Chu, Quincy, Gandhi, Leena, Carcereny, Enric, Sequist, Lecia V, Brunsvig, Paal et al.
DOI: 10.1016/j.jtho.2017.11.131

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

PMID: 29247830
Journal: Journal of Thoracic Oncology
Year: 2018
Reference: J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.
Impact factor:
Publication type: Paper in international publication
Authors: Akimov, Mikhail; Avsar, Emin; Barlesi, Fabrice; Besse, Benjamin; Brunsvig, Paal; Carcereny, Enric; Chouaid, Christos; Chu, Quincy; Felip, Enriqueta; Gandhi, Leena et al.
DOI: 10.1016/j.jtho.2017.11.131

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

PMID: 30052729
Journal: ANNALS OF ONCOLOGY
Year: 2018
Reference: Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
Impact factor: 13.926
Publication type: Clinical Trials
Authors: Lee, K-W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M-H, Chung, H-C, Evesque, L, Al-Batran, S-E, Park, S H, Lichinitser, M et al.
DOI: 10.1093/annonc/mdy264

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

PMID: 30052729
Journal: ANNALS OF ONCOLOGY
Year: 2018
Reference: Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
Impact factor:
Publication type: Clinical Trials
Authors: Al-Batran, S-E; Alsina, M; Bang, Y-J; Boku, N; Chung, H-C; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, K-W et al.
DOI: 10.1093/annonc/mdy264

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

PMID: 29936064
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2018
Reference: Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.
Impact factor: 7.191
Publication type: Clinical Trials
Authors: Moreno, Lucas, Casanova, Michela, Chisholm, Julia C, Berlanga, Pablo, Chastagner, Pascal B, Baruchel, Sylvain, Amoroso, Loredana, Melcon, Soledad Gallego, Gerber, Nicolas U, Bisogno, Gianni et al.
DOI: 10.1016/j.ejca.2018.05.002

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

PMID: 29936064
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2018
Reference: Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.
Impact factor:
Publication type: Clinical Trials
Authors: Aerts, Isabelle; Amoroso, Loredana; Baruchel, Sylvain; Bergeron, Christophe; Berlanga, Pablo; Bisogno, Gianni; Casanova, Michela; Chastagner, Pascal B; Chen, Nianhang; Chisholm, Julia C et al.
DOI: 10.1016/j.ejca.2018.05.002

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

PMID: 29593099
Journal: ONCOLOGIST
Year: 2018
Reference: Oncologist. 2018 Apr;23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. Epub 2018 Mar 28.
Impact factor: 5.306
Publication type: Paper in international publication
Authors: Edelman, Gerald, Lager, Joanne, Castell, Christelle, Jiang, Jason, Van Allen, Eliezer M, Wagle, Nikhil, Lindeman, Neal I, Sholl, Lynette M, Shapiro, Geoffrey I, Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2017-0691

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

PMID: 29593099
Journal: ONCOLOGIST
Year: 2018
Reference: Oncologist. 2018 Apr;23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. Epub 2018 Mar 28.
Impact factor:
Publication type: Paper in international publication
Authors: Castell, Christelle; Edelman, Gerald; Jiang, Jason; Lager, Joanne; Lindeman, Neal I; Rodon, Jordi; Shapiro, Geoffrey I; Sholl, Lynette M; Van Allen, Eliezer M; Wagle, Nikhil et al.
DOI: 10.1634/theoncologist.2017-0691

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

PMID: 29349598
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2018
Reference: Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.
Impact factor: 3.502
Publication type: Paper in international publication
Authors: Gonzalez, Iria, Lopez-Martin, Jose, Welt, Anja, Levy, Christelle, Joly, Florence, Michielin, Francesca, Jacob, Wolfgang, Adessi, Celine, Moisan, Annie, Meneses-Lorente, Georgina et al.
DOI: 10.1007/s10637-018-0562-4

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

PMID: 29349598
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2018
Reference: Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.
Impact factor:
Publication type: Paper in international publication
Authors: Adessi, Celine; Albanell, Joan; Cejalvo, Juan Miguel; Ceppi, Maurizio; Cervantes, Andres; Cortes, Javier; Dieras, Veronique; Gonzalez, Iria; Hasmann, Max; Jacob, Wolfgang et al.
DOI: 10.1007/s10637-018-0562-4

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

PMID: 30156984
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2018
Reference: J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.
Impact factor: 26.303
Publication type: Paper in international publication
Authors: Ahn, Myung-Ju, Vansteenkiste, Johan F, Su, Wu-Chou, Felip, Enriqueta, Chia, Vincent, Glaser, Sabine, Pultar, Philippe, Zhao, Sylvia, Peng, Bin, Akimov, Mikhail et al.
DOI: 10.1200/JCO.2018.77.7326

Publications

Publications searcher

Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease.

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

PHARMACOKINETIC STUDY OF CONVERSION BETWEEN TWO FORMULATIONS OF ONCE-DAILY EXTENDED-RELEASE TACROLIMUS IN STABLE LUNG TRANSPLANT PATIENTS.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

Pharmacological Treatment of Insomnia Symptoms in Individuals with Substance Use Disorders in Spain: A Quasi-Experimental Study.

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

Pharmacology of Symtuza((R)) (DRV/c/FTC/TAF).

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Phase 3, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Patronage:

Collaborating:

Accreditations: